Georgiana Toma: Addressing Iron Deficiency Without Anemia
Georgiana Toma, Hematology resident at the University Emergency Hospital of Bucharest, shared a post on LinkedIn:
“Iron Deficiency Without Anemia
How many of our patients struggle with chronic fatigue, ‘brain fog’, or exercise intolerance, only to be told their labs are ‘perfectly normal’ because their Hemoglobin is within range?
As clinicians, we are trained to treat Anemia.
But modern Hematology is sounding the alarm on a much more subtle predator: Iron Deficiency Without Anemia (IDWA).
The ‘Normal Hemoglobin’ Trap
A patient can have a Hemoglobin of 14 g/dL and still be cellularly ‘starving’ for iron.
Iron isn’t just for making red blood cells; it’s a critical cofactor for mitochondrial function, DNA synthesis, and neurotransmitter metabolism.
When we only look at the CBC, we miss the Sideropenia that is sabotaging our patients’ recovery and quality of life.
A Multidisciplinary challenge:
The evidence for treating IDWA (typically defined as Ferritin <30–50 ng/mL) is now robust across specialties:
- cardiology: the FAIR-HF and CONFIRM-HF trials revolutionized the field. Correcting iron deficiency in heart failure patients—regardless of anemia status—improves ejection fraction and reduces hospitalizations.
- neurology: iron is the ‘engine’ for dopamine synthesis. In Restless Legs Syndrome (RLS), clinical guidelines now suggest targeting Ferritin levels above 75 ng/mL, far beyond standard ‘normal’ lab ranges.
- gynecology: we often focus on stopping the flow (menorrhagia) but neglect the cognitive and physical toll of depleted iron stores that persist long after the bleeding is managed.
- sportsmedicine : sideropenia impairs muscular oxidative capacity and increases lactate production, even when oxygen-carrying capacity (Hb) is intact.
Should we stop asking ‘Is the patient anemic?’ and start asking ‘Are the patient’s iron stores optimized for their specific pathology?’
Standard lab ranges for Ferritin (often starting at 15 ng/mL) frequently fail to account for the functional needs of a failing heart or a developing brain.”

Stay updated on all scientific advances with Hemostasis Today.
-
May 6, 2026, 14:02Abdul Mannan: Anemia in Myelofybrosis – Five Fires Behind One Falling Hb
-
May 6, 2026, 14:00Mona Alfaraj: Advancing Care in Inherited Platelet Disorders at 2nd International Hematology and Hemostasis Conference
-
May 6, 2026, 13:56Mahesan Subramaniam: Why Delayed Cord Clamping Benefits Newborn Health
-
May 6, 2026, 13:44Wolfgang Miesbach: Octreotide as a First‑Line Systemic Option in VWD Patients With Angiodysplasia‑Related GI Bleeding
-
May 6, 2026, 13:42Irogue Igbinosa: Rethinking Iron Deficiency in Pregnancy with Intravenous Therapy
-
May 6, 2026, 13:34Manaf Aljishi: Three Posters Presented at the Hematology and Hemostasis Conference 2026
-
May 6, 2026, 13:33David Ferreira: Insights from the 1st National Meeting of Young Immunohematologists in Abrantes
-
May 6, 2026, 13:22Nicholas Lee: Honored to Join ASH CRTI Program for Aplastic Anemia Research
-
May 6, 2026, 13:16Mehari Gebreyohanns: Transition from Alteplase to Tenecteplase Is Full Steam Ahead in Texas